Roche introduces mobile blood gas analyzer for hospital point-of-care testing in the United States
Rotkreuz/Switzerland, 18 July 2012
FDA approval grants immediate marketing of the cobas® b 123 POC system in the U.S.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas b 123 POC system, a mobile blood gas analyzer designed for hospital point-of-care settings. Healthcare professionals benefit from on the spot assessment of a patient's oxygenation levels and electrolyte balance, among others. With seamless connectivity to the IT environment, either wirelessly or via a network port, the cobas b 123 POC system uses Roche’s powerful point of care data management systems – cobas bge link software and cobas IT 1000 application.
“With the US inauguration of the cobas b 123 POC system from Roche, a high level of testing accuracy for vital parameters and unrivalled ease of use at the point of care enables healthcare professionals for improved decision making while reducing their potential maintenance requirements. This gives them the opportunity to focus on what matters most, their patient’s needs”, said Jeremy Moss, Global Head of Point of Care at Roche Professional Diagnostics in Rotkreuz/Switzerland.
Quick results of 15 parameters in 2 minutes
With the patented thick-film sensor technology and a broad assay menu that includes lactate testing, the cobas b 123 POC system offers quick results for 15 important critical-care blood gas and electrolyte tests with a turnaround time of just 2 minutes. Its mobile cart installation facilitates flexible use in a variety of areas, from the laboratory to the intensive care unit.
Four-level clot protection system saves time and costs
The analyzer’s unparalleled, four-level clot protection system helps prevent downtime which may be caused by the introduction of clots to the system, potentially leading to reagent failures - a major issue for healthcare facilities, because replacing the pack for failures due to clots takes time away from patient care, wastes reagents and increases customer costs.
Simplified workflow and regulatory compliance
The cobas b 123 POC system offers automatic linearity testing and calibration to simplify both workflow and regulatory compliance. Roche’s Electronic Quality Assurance Program (eQAP) also gives hospitals access to anonymous linearity and quality control peer performance data to make it easier to benchmark their quality control (QC) data.
Double award win for medical design excellence
Due to its convenience in ease of use, the cobas b 123 POC system won the golden Medical Design Excellence Award (MDEA) and the Red Dot Design Award (the “Red dot”) for excellent product design in medical care in 2011.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com
All trademarks used or mentioned in this release are protected by law.